Day: September 3, 2025

Aspire Biopharma Announces Breakthrough Final Results from Clinical Trial of Investigational New Sublingual Aspirin Product for Treatment of Suspected Acute Myocardial Infarction (Heart Attack)

Aspire's sublingual aspirin formulation significantly inhibited serum thromboxane B2 (TxB2) within the first two minutes after dosingTxB2 is a biomarker...

Zomedica Strengthens UK Market Position with Strategic Distribution Agreement for High-Growth Veterinary Innovation Portfolio

Strategic partnership with Pioneer Veterinary Products Limited expands Zomedica's presence in the UK veterinary market through distribution of its leading...

Autonomix Medical, Inc. Demonstrates Sustained Pain Reduction, Quality of Life Gains and 100% Zero Opioid Use in Longer-Term Post Hoc Analysis from PoC 1 Study

New longer-term post hoc analysis results of responders (n=6)1 showed long-lasting, durable pain reduction of nearly 66%, or a mean...

Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation

Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA...

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse...

error: Content is protected !!